Hashash JG, Thompson CC, Wang AY
(Source: lan Clinic, June 2026) Relative Risk Compared to Placebo A systematic review published in the Journal of Clinical Investigation quantified the increased nausea risk for each newer-generation therapy against placebo: Worth noting: Semaglutide and tirzepatide show nearly identical nausea risk 2.95 versus 2.90 relative to placebo
While side effects such as nausea can occur, our providers personalize your dosing schedule to keep them to a minimum
The fact that 2 drugs with the same chemical composition have different names, indications and list prices only underscores the complexities plan sponsors must account for when developing a GLP-1/GIP approach
Patients who maintain or build muscle during GLP-1 treatment experience less metabolic slowdown and better weight maintenance after stopping
Our dedicated team is here to support your journey toward a healthier, more active lifestyle